Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Runnebaum

Showing results (411-420 of 452) with videos related to

Pageof 46
Sort By:
British Journal of Cancer|September 16, 1999
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutationsS Wang-Gohrke, W Weikel, H Risch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III studyVolker Moebus, Christian Jackisch, Hans-Joachim Lueck, et al.
Tumour Virus Research|July 27, 2023
Association of two genomic variants with HPV type-specific risk of cervical cancerFinja Seifert, Rieke Eisenblätter, Julia Beckmann, et al.
International Journal of Surgery (London, England)|February 24, 2025
Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysisFabian Trillsch, Bastian Czogalla, Sven Mahner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup StudyJ Sehouli, I B Runnebaum, C Fotopoulou, et al.
JCO Precision Oncology|January 30, 2023
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 TrialEric Pujade-Lauraine, Jessica Brown, Alan Barnicle, et al.
Gynecologic Oncology|December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trialMansoor R Mirza, Line Bjørge, Frederik Marmé, et al.
Pharmacogenetics|October 23, 2001
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptivesI B Runnebaum, S Wang-Gohrke, D Vesprini, et al.
The Lancet. Oncology|June 12, 2010
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational studyMaaike H Oonk, Bettien M van Hemel, Harry Hollema, et al.
Gynecologic Oncology|October 3, 2015
Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) IN C Te Grootenhuis, A G J van der Zee, H C van Doorn, et al.
Pageof 46

Showing results (411-420 of 452) with videos related to

Sort By:
Pageof 46
British Journal of Cancer|September 16, 1999
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutationsS Wang-Gohrke, W Weikel, H Risch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III studyVolker Moebus, Christian Jackisch, Hans-Joachim Lueck, et al.
Tumour Virus Research|July 27, 2023
Association of two genomic variants with HPV type-specific risk of cervical cancerFinja Seifert, Rieke Eisenblätter, Julia Beckmann, et al.
International Journal of Surgery (London, England)|February 24, 2025
Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysisFabian Trillsch, Bastian Czogalla, Sven Mahner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup StudyJ Sehouli, I B Runnebaum, C Fotopoulou, et al.
JCO Precision Oncology|January 30, 2023
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 TrialEric Pujade-Lauraine, Jessica Brown, Alan Barnicle, et al.
Gynecologic Oncology|December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trialMansoor R Mirza, Line Bjørge, Frederik Marmé, et al.
Pharmacogenetics|October 23, 2001
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptivesI B Runnebaum, S Wang-Gohrke, D Vesprini, et al.
The Lancet. Oncology|June 12, 2010
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational studyMaaike H Oonk, Bettien M van Hemel, Harry Hollema, et al.
Gynecologic Oncology|October 3, 2015
Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) IN C Te Grootenhuis, A G J van der Zee, H C van Doorn, et al.
Pageof 46